Barclays Lowers IPSEN S A/S (OTCMKTS:IPSEY) to Equal Weight

Barclays downgraded shares of IPSEN S A/S (OTCMKTS:IPSEY) from an overweight rating to an equal weight rating in a report issued on Monday, The Fly reports.

Separately, ValuEngine raised shares of IPSEN S A/S from a sell rating to a hold rating in a report on Wednesday, October 2nd. Five research analysts have rated the stock with a hold rating, IPSEN S A/S presently has a consensus rating of Hold.

Shares of IPSEY stock opened at $22.00 on Monday. IPSEN S A/S has a 12-month low of $21.55 and a 12-month high of $35.97. The firm has a market capitalization of $7.80 billion, a price-to-earnings ratio of 12.64 and a beta of 0.56. The firm has a fifty day moving average of $26.37 and a 200-day moving average of $27.85.

IPSEN S A/S Company Profile

Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.

Recommended Story: Market Timing – The Benefits and the Danger

The Fly

Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit